NCT06336798View on ClinicalTrials.gov

Bioenergetic Effect of Pioglitazone in CLD-PH

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Pulmonary HypertensionPulmonary Hypertension Due to Lung Diseases
Interventions
DRUG

Pioglitazone 30mg

Study participants will take Pioglitazone 30 mg PO daily

DRUG

Placebo

Study participants will take a placebo PO daily

DIAGNOSTIC_TEST

Labs

Labs will be performed for Urine HCG, Complete Blood count (CBC), Chemistry Panel, Fasting lipids, insulin, glucose, and Bioenergetic analysis (platelets).

Trial Locations (1)

30322

RECRUITING

Emory Healthcare System, Atlanta

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Emory University

OTHER